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Background: The natural history of prostate cancer is highly variable and difficult to predict. We report on the prognostic value of
phosphatase and tensin homologue (PTEN) loss in a cohort of 675 men with conservatively managed prostate cancer diagnosed
by transurethral resection of the prostate.
Methods: The PTEN status was assayed by immunohistochemistry (PTEN IHC) and fluorescent in situ hybridisation (PTEN FISH).
The primary end point was death from prostate cancer.
Results: The PTEN IHC loss was observed in 18% cases. This was significantly associated with prostate cancer death in univariate
analysis (hazard ratio (HR)¼ 3.51; 95% CI 2.60–4.73; P¼ 3.1 10 14). It was highly predictive of prostate cancer death in the 50% of
patients with a low risk score based on Gleason score, PSA, Ki-67 and extent of disease (HR¼ 7.4; 95% CI 2.2–24.6; P¼ 0.012) ), but
had no prognostic value in the higher risk patients. The PTEN FISH loss was only weakly associated with PTEN IHC loss (k¼ 0.5).
Both PTEN FISH loss and amplification were univariately predictive of death from prostate cancer, but this was not maintained in
the multivariate analyses.
Conclusion: In low-risk patients, PTEN IHC loss adds prognostic value to Gleason score, PSA, Ki-67 and extent of disease.
Differentiation of aggressive from indolent tumours remains a high
priority for the appropriate management of prostate cancer and the
avoidance of unnecessary treatments and side effects in patients
with indolent disease. We have investigated over 40 potentially
prognostic biomarkers, including cell surface, cytoplasmic and
nuclear markers and chromosomal rearrangements, for their
ability to predict prostate cancer-specific survival. Although many
were univariately significant, few were significant in multivariate
analysis when Gleason score and baseline PSA were also included
in the model (Cuzick et al, 2006; Attard et al, 2008; Berney et al,
2009; Foster et al, 2009; Kudahetti et al, 2009; Rajab et al, 2010a, b).
Only an RNA-based cell cycle progression score (Cuzick et al,
2011, 2012), extent of disease (% chips) (Rajab et al, 2010a) and the
immunohistochemistry (IHC) proliferation biomarker Ki-67
(Berney et al, 2009) provided substantial improvement on
assessment of prognosis based on Gleason score and PSA alone.
Phosphatase and tensin homologue (PTEN) 10q23-24 muta-
tions have long been associated with prostate cancer (Gray et al,
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1998) and PTEN protein and genomic losses have been correlated
with poor prognosis (McMenamin et al, 1999; Schmitz et al, 2007;
Yoshimoto et al, 2007).
In combination with other genes within the PTEN tumour-
suppressor pathway, IHC-detectable PTEN loss was the most
significant prognostic protein in breast cancer and correlated
significantly with poor patient outcome in prostate cancer and
bladder cancer cohorts (Saal et al, 2007). As part of a four gene
signature, PTEN expression was shown to be prognostic of PSA
biochemical recurrence and lethal metastasis in a radical
prostatectomy cohort (Ding et al, 2011).
The prognostic value of PTEN gene status has been suggested
using an mRNA microarray signature for a range of pathways in
281 patients (Markert et al, 2011) where a cluster exhibiting a
stem cell like signature and also P53 and PTEN loss had a very poor
outcome. In molecular subsets based on fluorescent in situ hybridisa-
tion (FISH)-detected ERG and ETV1 gene patterns, PTEN was
found to be a useful prognostic indicator of prostate cancer-specific
death (Reid et al, 2010) and biochemical recurrence (Krohn et al,
2012).
Less cumbersome and more comprehensive IHC studies have
supported the value of PTEN loss in high-risk patients treated by
radical prostectomy (Lotan et al, 2011) and have found PTEN to be
a weakly independent prognostic factor for progression-free
survival in prostate cancer (Antonarakis et al, 2012). In contrast,
Bedolla et al (2007) found that, by itself, PTEN was not seen as a
good predictor of biochemical recurrence, although it was better in
combination with Akt. Combined PTEN IHC and FISH studies
have suggested a role for both cytoplasmic and nuclear PTEN loss
in progression, but a trend between PTEN loss and prostate cancer
death was not significant (McCall et al, 2008). Conflicting results
may be partly attributed to differences in methodology (Sangale
et al, 2011). In a subset of the current cohort, we previously
reported on PTEN loss using FISH to detect gene loss (Reid et al,
2010). In that analysis, PTEN gene loss showed an association with
prostate cancer-specific mortality in univariate but not multivariate
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Figure 1. Consort diagram: PTEN cohort derivation.
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analyses. An apparent interaction, with ERG/ETV1 gene rearran-
gement (ETS), was also observed.
Here we report on the prognostic value of PTEN status for death
from prostate cancer evaluated by IHC and FISH in a large cohort
of men with conservatively treated prostate cancer with long-term
follow-up.
MATERIALS AND METHODS
Patients. Potentially eligible cases of prostate adenocarcinoma
diagnosed by TURP were identified from six cancer registries in
Great Britain. Case notes from collaborating hospitals were
reviewed to assess patient eligibility and confirm they had
conservatively managed clinically localised disease, as described
previously (Cuzick et al, 2006). Briefly, men were included in this
study if they had conservatively treated clinically localised prostate
cancer diagnosed by TURP between 1990 and 1996 (inclusively),
were younger than 76 years at the time of diagnosis and had a
baseline PSA measurement. Patients treated with radical prosta-
tectomy or radiation therapy within the first 6 months after
diagnosis, or who died or showed evidence of metastatic disease
within 6 months of diagnosis or had a baseline PSA4100 ngml 1
were excluded. Men who had hormone therapy before the
diagnostic biopsy were also excluded.
Cases were diagnosed between 1990 and 1996 and the last
follow-up took place in December 2009. Deaths were divided into
those from prostate cancer and those from other causes, according
to the World Health Organisation standardised criteria (WHO,
2010). Approval was obtained from the Northern Multicentre
Research Ethics Committee, followed by local ethics committee
approval at each collaborating hospital.
The PTEN IHC and FISH assays were conducted on a tissue
microarray of up to six 600 mm diameter cancerous cores per
biopsy block of formalin-fixed, paraffin-embedded tissue from
patients diagnosed by TURP.
IHC assay. The PTEN IHC loss was assayed with rabbit
monoclonal antibody 138G6 (Cell Signaling Technology Inc.,
Danvers, MA, USA). The assay was performed at Myriad Genetics,
Inc. (Salt Lake City, UT, USA) and interpreted by a pathologist (ZS).
A negative sample was regarded as having no staining in either the
cytoplasmic or nuclear cellular compartment; for positive samples,
only cytoplasmic staining was scored (Sangale et al, 2011). In both
the nucleus and the cytoplasm, PTEN staining was seen, but only
cytoplasmic staining was used in the scoring. Where multiple cores
per individual were available, the average PTEN score was used. The
PTEN IHC status was dichotomised as present (positive), or loss
(negative), defined as o10% tumour cells staining positive.
FISH assay. The PTEN FISH loss was also assayed in the same
tissue microarray, using a directly labelled chromosome 10
centromere probe and two overlapping BAC probes to the PTEN
locus (Reid et al, 2010). For each core PTEN FISH status was
scored as normal, gene amplification or loss (heterozygous or
homozygous). For multiple cores, an individual was assigned the
greatest degree of loss seen in any core. Cases showing both loss
and amplification were omitted (N¼ 9). For ETS subgroups, cases
were defined by previous ERG/ETV1 FISH analysis as being either
normal or rearranged and excluded if no information was available
(N¼ 1). Cases with PTEN FISH homozygous loss included all
those where both copies of the PTEN gene were deleted or one
copy was deleted and the second copy dysfunctional because of
associated ETS gene rearrangements.
Statistical analysis. The primary end point was time to death
from prostate cancer, which was assessed using a proportional
hazards model. Observations were censored on the date of last
follow-up, or at death from other causes. Covariates evaluated were
centrally reviewed Gleason score, baseline PSA value, clinical stage,
extent of disease (proportion of positive chips), age at diagnosis
and Ki-67 score (% cells positive).
The concentration of PSA was modelled as the natural
logarithm of (1þPSA (ngml 1)). For simplicity, Gleason scores
were grouped into less than 7, equal to 7 and greater than 7.
Gleason 3þ 4 and 4þ 3 was combined because they previously
showed little difference in outcome (Cuzick et al, 2006).
All variables were available for 619 men and were combined in a
multivariate proportional hazards model to create an overall clinical
score that was evaluated as the linear predictor of the multivariate
model including Gleason, PSA, Ki-67 and extent of disease.
All P-values were two sided and 95% CIs and P-values, obtained
from partial likelihoods of proportional hazards models, were
based on w2 statistics with 1 degree of freedom (d.f.), unless
otherwise indicated. The main assessment was by univariate and
multivariate analyses of the prognostic value of PTEN status on
death from prostate cancer. For the multivariate Cox proportional
hazards models, forward stepwise regression was used. Statistical
analyses were done with STATA (version 11.2, StataCorp, 4905
Lakeway Drive, College Station, TX, USA).
RESULTS
PTEN IHC status. The PTEN IHC staining was recorded for 1729
cancer cores from 675 men. The cohort derivation is shown in
Figure 1. The PTEN status was scored as negative in 119 (18%) and
positive in 556 (82%) cases. Scores were derived from a single core
Figure 2. Prostatic adenocarcinoma showing PTEN-deficient (A) and
PTEN-positive (B) staining by immunohistochemistry.
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in 132 (20%) cases, from two cores in 238 (35%) men, from three
cores in 115 (17%) men, from four cores in 179 (27%) men, from
five cores in 6 (1%) men and from six cores in 5 (1%) men.
Examples of positively and negatively stained sections are shown in
Figure 2. Heterogeneity of staining within cores was seen ino1% of
samples. The vast majority (95%) of PTEN IHC-assessed tumours
were either negative on all cores (n¼ 118) or positive on all cores
(n¼ 524). There were strong correlations (Po0.001) between PTEN
IHC and Gleason score, PSA and Ki-67, with PTEN loss more
common in cases with Gleason score 47, Ki-67 score 45% or
baseline PSA 410 ngml 1 (Supplementary Table 1).
In a univariate analysis PTEN IHC loss was a significant
predictor of prostate cancer death in. The hazard ratio (HR) was
3.51 (95% CI 2.60–4.73; w2 (1 d.f.)¼ 57.7; P¼ 3.1 10 14;
Table 1). In a multivariate analysis with Gleason score, PSA and
PTEN IHC based on the 625 men for whom all covariate scores
were available, PTEN IHC added significantly to the overall
predictive ability (HR¼ 1.47; 95% CI 1.07–2.04; P¼ 0.02; Table 1).
When Ki-67 and extent of disease, as assessed by percentage of
TURP chips containing cancer, were added to the multivariate
model, the contribution from PTEN IHC (P¼ 0.22) was markedly
reduced. However, the multivariate analysis was strongly influ-
enced by patients with poor risk factors.
There was strong evidence of interaction of PTEN IHC with
Gleason score (P¼ 0.008, 1 d.f)., PSA (P¼ 0.001, 1 d.f.), Ki-67
(P¼ 0.001, 1 d.f). and extent of disease (P¼ 0.001, 1 d.f.) in
predicting outcome, and PTEN appears to be predictive only in
men with low Gleason score, low PSA, low Ki-67 or low extent of
disease (Figures 3 and 4).
The best linear predictor using standard factors was given by
Gleason, PSA, Ki-67 and extent of disease. A prognostic model was
constructed using these factors and a linear predictor was obtained.
This was designated the clinical score and when scaled to vary
approximately between 0 and 100 was given by:
Clinical score¼ 16.2x(Gleason score 7)þ 30.2x(Gleason
score47)þ 6.6x log(1þPSA(ngml 1))þ 17.2x(Ki-6745%)þ 0.3x
(extent of disease)þ 38.7.
A histogram of the clinical scores is shown in Figure 5 and it
was strongly predictive of outcome (Table 1). When stratified by
clinical score PTEN IHC was found to strongly predict outcome
only in the lowest 50% of this score distribution (Figures 3 and 4)
but not for high values. There was a significant interaction of
PTEN with this score (P¼ 0.047).
PTEN FISH status. The PTEN FISH staining was recorded for
1672 cancer cores from 652 men. Cases were each assigned a PTEN
FISH status of normal, amplification, heterozygous or homozygous
loss. Examples of FISH staining for this population have been
shown in our previous work (Reid et al, 2010). The PTEN FISH
was analysed as a categorical variable in these four groups and also
in three groups with the few cases of heterozygous loss combined
with homozygous loss; normal was used as the reference group.
Nine patients with evidence of both heterozygous loss and
amplification were excluded. For PTEN FISH analysis in four
categories, an additional eight patients with both heterozygous loss
and missing ETS status (ambiguous loss status) were excluded. In
univariate analysis of PTEN FISH in three categories, PTEN FISH
loss was significantly predictive of prostate cancer death
(HR¼ 2.46; 95% CI 1.72–3.51; Wald’s test P¼ 8 10 7).
Univariate analysis of PTEN FISH with distinct heterozygous loss
and homozygous loss indicated the latter group was the most at
risk (HR¼ 2.77; 95% CI 1.89–4.05; Wald’s test P¼ 1.8 10 7).
However, in a multivariate analysis including Gleason score, PSA,
Table 1. Univariate and multivariate analyses of prostate cancer death: survival results for PTEN IHC loss (PTEN), with Gleason score (G), baseline PSA (P),
Ki-67 (K) and extent of disease (C)
Multivariate
Univariate PTEN, G, P (N¼675) PTEN, G, P, K, C (N¼619)
Na HR (95% CI) v2 (P-value) HR (95% CI) v2 (P-value) HR (95% CI) v2 (P-value)
PTEN IHC (675)
Normal 556 1b 57.68 (3.110 14) 1b 5.37 (0.021) 1b 1.52 (0.218)
PTEN loss 119 3.51 (2.60–4.73) 1.47 (1.07–2.04) 1.24 (0.88–1.73)
Gleason (675)
o7 327 1b 145.22 (1.910 33) 1b 52.23 (4.9 1013) 1b 18.74 (1.5105)
7 181 3.51 (2.35–5.26) 1.98 (1.25–3.11) 1.77 (1.09–2.88)
47 167 8.45 (5.83–12.26) 4.54 (2.93–7.04) 2.91 (1.76–4.81)
log(1þPSA) (675) 1.93 (1.68–2.20) 98.32 (3.610 23) 1.51 (1.29–1.76) 28.77 (8.2 108) 1.30 (1.09–1.54) 8.75 (3.1103)
Ki-67 (625)
p5% 481 1b 80.35 (3.110 19) 1b 15.14 (10 6)
45% 144 4.21 (3.13–5.65) 1.93 (1.39,2.67)
Extent of diseasec (669) 1.25 (1.20–1.30) 128.95 (7.010 30) 1.10 (1.04–1.16) 12.83 (3.4104)
Clinical score (619)
oMedian 310 1 173.92 (1039)
50–75th Percentile 154 4.29 (2.77–6.66)
475th Percentile 155 11.76 (7.85–17.62)
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; IHC¼ immunohistochemistry; PSA¼prostate-specific antigen; PTEN¼phosphatase and tensin homologue.
aSample size for univariate analysis.
bReference category.
cExtent of disease (%) is scaled to be between 0 and 10, so that the hazard ratio corresponds to every 10% increase.
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Ki-67 and extent of disease (Table 2), the predictive value was lost,
as for PTEN IHC. Similarly, PTEN FISH amplification was
significantly predictive of prostate cancer death (HR¼ 1.75; 95%
CI 1.23–2.50) in univariate analysis, but not in the multivariate
analyses (Table 2). There was no evidence of interaction of PTEN
FISH (normal, amplification, loss) with Gleason score (P¼ 0.99) or
our clinical score (P¼ 0.4). We did not find PTEN FISH (normal,
amplification, loss) to be more predictive in the low Gleason score
and low clinical score (HR¼ 1.2; 95% CI 0.4–3.1 for amplification
and HR¼ 1.4; 95% CI 0.3–6.1 for loss).
In contrast to our previous analysis based on a subset of these
cases, we found no evidence of an interaction of PTEN FISH
(normal, amplification, loss) with ETS (P¼ 0.2).
PTEN IHC status and PTEN FISH status. Both PTEN IHC and
PTEN FISH results were available for 568 cases. We are interested
in comparing PTEN IHC loss with PTEN FISH loss (heterozygous
loss combined with homozygous loss). Considering both PTEN
FISH amplification and normal as one group, Cohen’s k for PTEN
FISH loss and PTEN IHC loss was 0.5 (Po0.001). Excluding
those cases classified as PTEN FISH amplification, Cohen’s k for
PTEN IHC and PTEN FISH (n¼ 439) was also 0.5 (Po0.001).
PTEN FISH loss was seen in 63% of men (56 out of 89)
when PTEN IHC was negative and 11% of men (38 out of 350)
when PTEN IHC was positive. In a bivariate analysis (excluding
PTEN FISH amplification cases), PTEN IHC loss was a much
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stronger predictor of prostate cancer death than PTEN FISH loss
(w2¼ 42 and 0.5, respectively), and PTEN FISH did not add
significant prognostic information when PTEN IHC was in the
model.
DISCUSSION
Variable results have been seen in different IHC studies of PTEN.
The majority of the commercially available PTEN antibodies are
directed against the same C-terminal epitope as 138G6, the
antibody used in this study (Sangale et al, 2011). The antibody
138G6 is directed against the extreme carboxy-terminal sequence
of human PTEN protein, and therefore, will only stain full-length
protein. Thus, the presence of nonfunctional truncated protein
should not confound our results.
A second and perhaps more important reason for the variability
between studies of PTEN expression is the differences in antibody
specificity. In a previous work (Sangale et al, 2011), an evaluation
of 11 PTEN antibodies showed that 138G6 was the most specific of
the commercially available antibodies. In a panel of control tissues
that were molecularly characterised for PTEN status, most of the
PTEN antibodies (with the exception of 138G6) were found to
have poor sensitivity, specificity or both. This assessment included
other antibodies directed at C-terminal peptides and two
antibodies directed against the full-length recombinant protein.
Their conclusions were confirmed by an independent study (Lotan
et al, 2011).
In the current analysis, PTEN IHC added prognostic informa-
tion for prostate survival in univariate analysis, but in multivariate
analysis the effect was only apparent when other markers indicated
a good prognosis and was not additionally informative when other
markers indicated poor prognosis. This is especially relevant for
men with Gleason¼ 6 where additional markers are particularly
needed. Here it retained prognostic value in multivariate analysis
with a high observed hazard ratio. It was also highly predictive in
the low-risk group with PSA p10 ngml 1. For men in the lowest
50% of the clinical score, based on Gleason score, PSA, Ki-67 and
extent of disease, PTEN IHC was a strong independent predictor
with a hazard ratio in excess of seven-fold. Even greater
proportions would be scored as low risk in areas where PSA
screening is routinely practiced.
The assessment of PTEN using this antibody was very
reproducible and very few patients had conflicting results in
different cores, suggesting that it is highly reproducible across
laboratories. It is also less expensive than molecular markers
(Cuzick et al, 2006) and may have a role in triaging low-risk
patients.
In multivariate models, PTEN FISH loss was not as strong a
predictor as PTEN IHC loss and did not add independent
information.
The poor correlation of PTEN FISH status with IHC status
contrasts with a previous report for the same antibody (Reid et al,
2012). This may be partly explained by the extent of heterogeneity
across the cores observed in the current study; staining was consistent
across individual cores from the same patient in 95% cases stained by
PTEN IHC, but only 75% cases stained by PTEN FISH.
The reason for PTEN loss being important only in low-risk
patients is not clear and requires replication in another study. It
suggests that PTEN may be involved at an early stage in a pathway
associated with disease development, and when this or other
pathways are sufficiently dysregulated to lead to cancers with an
elevated Gleason Score or a large extent, the effect is overridden.
However, we know of no direct mechanistic data to confirm this.
The fact that PTEN loss is a much stronger factor in univariate
analyses than in multivariate ones also suggests that it is only a part
of the carcinogenic process and further changes are needed before
aggressive tumours develop.
These findings require replication in an independent data set
and also need to be established for patients diagnosed by needle
biopsy and managed conservatively. The value of PTEN in
predicting recurrence or death from prostate cancer in men who
receive radical treatment also needs to be established.
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Table 2. Univariate and multivariate PTEN FISH analysis hazard ratios (HRs) for normal vs amplification (amp) vs loss (any, heterozygous (het), homozygous
(hom)), with Gleason score (G) and baseline PSA (P) only, and also including Ki-67 (K) and extent of disease (C)
Univariate Multivariate
(N¼643) PTEN, G, P (N¼643) PTEN, G, P, K, C (N¼575)
PTEN FISH N HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Normal 399 1a 1a 1a
Amp 140 1.75 (1.23–2.50) 0.002 1.30 (0.91–1.87) 0.15 1.34 (0.91–1.96) 0.14
Loss (any) 104 2.46 (1.72–3.51) 8.0107 1.20 (0.82–1.73) 0.35 1.19 (0.81–1.76) 0.38
Het 18 1.92 (0.89–4.14) 0.1 0.91 (0.42–1.98) 0.81 0.84 (0.38–1.85) 0.66
Hom 78 2.77 (1.89–4.05) 1.8107 1.33 (0.89–1.98) 0.16 1.34 (0.88–2.03) 0.17
Abbreviations: CI¼ confidence interval; FISH¼ fluorescent in situ hybridization; PTEN¼phosphatase and tensin homologue.
Patients with cores showing both amplification and loss were excluded (N¼ 9). For PTEN FISH analysis in four categories, cases with heterozygous loss and missing ETS status (N¼ 8) were
excluded.
aReference category.
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DISCLAIMER
The PTEN status was assayed blind to all other data by Myriad
Genetics (IHC) and ICR (FISH). Analysis was conducted at QMUL
under the direction of Professor Cuzick, following a predefined
Statistical Analysis Plan. Interpretation of the data was done jointly
by all authors, but the final content of this report was determined
by non-corporate authors.
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APPENDIX
Investigators in participating regional cancer registries, research
centres and hospital trusts are listed below. Members of the
Transatlantic Prostate Group are designated by an asterisk.
Thames Cancer Registry: Henrik Møller*, Shirley Bell
(deceased), K Linklater, J Ottey V Fisher; Ashford & St Peter’s:
M Hall, N Harvey Hills; Barnet & Chase Farm: H Reid; Brighton
and Sussex: N Kirkham, P Thomas; Bromley: D Nurse; Dartford &
Gravesham: I Dickinson, P Thebe; East & North Hertfordshire: D
Hanbury, M Ali-Izzi; Eastbourne: C Moffatt; Epsom & St Helier: M
Bailey, L Temple; Essex Rivers Healthcare; W Aung, C Booth;
Frimley Park: B Montgomery, P Denham; Greenwich Healthcare:
N Cetti, P Pinto; Guy’s & St Thomas’s: A Chandra, T O’Brien;
Hammersmith Hospitals: N Livni; Havering Hospitals: I Saeed;
Hillingdon: F Barker, T Beaven; King’s Healthcare: G Muir, Z
Khan; Kingston: C Jameson; Lewisham; A Giles; Mayday
Healthcare; N Arsanious, A Arnaout; The Medway: E Boye; Mid
Essex Hospitals: Mid Kent: M Boyle; North West London
Hospitals: M. Jarmulowicz; Royal Free Hampstead: RJ Morgan, A
Bates; St Bartholomew’s and The Royal London Hospitals: F
Chinegwundoh*, RTD Oliver*, D Berney*; Wolfson Institute of
Preventive Medicine, Queen Mary University of London: J
Cuzick*, G Fisher*; Institute of Cancer Research, Sutton: C
Cooper*; Royal Surrey County: S De Sanctis; Southend: M
Chappell; St George’s, London: R Kirby, C Corbishley; St Mary’s,
London: A Patel, M Walker; West Hertfordshire: J Crisp, W
Riddle; Worthing & Southlands Hospitals: J Grant.
Northern & Yorkshire Cancer Registry & Information Service:
David Forman*, C Storer, C Bennett, C Spink; Airedale: I Appleyard,
JO’Dowd; Hull & East Yorkshire: J Hetherington, A MacDonald;
The Leeds Teaching Hospitals: P Whelan, P Quirke and P Harnden.
Oxford Cancer Intelligence Unit: Monica Roche*, Sandra
Edwards, S Bose, P Hall; Heatherwood & Wexham Park: M Ali,
O Karim; Milton Keynes: E Walker, S Jalloh; Northampton:
M Miller, A Molyneux; Oxford Radcliffe: S Brewster, D Davies;
Royal Berkshire & Battle: P Malone, C McCormick; Stoke
Mandeville: J Greenland and A Padel.
Welsh Cancer Intelligence & Surveillance Unit: John Steward*,
Shelagh Reynolds, Lynda Roberts, Judith Adams; Ceredigion and
Mid Wales: J Edwards, CGB Simpson; Conwy & Denbighshire: A
Dalton, V Srinivasan; NE Wales: A De Bolla, C Burdge; Gwent
Healthcare: W Bowsher, M Rashid; Swansea: M Lucas, C O’Brien;
Cardiff & Vale: M Varma.
Scottish Cancer Registry: David Brewster*; The Lothian
University Hospitals, J Royle, K Grigor; North Glasgow University
Hospitals, D Kirk, A Milano and R Reid.
Merseyside & Cheshire Cancer Registry: Lyn Williams*,
R Iddenden; Royal Liverpool University Hospital, CS Foster* and
P Cornford.
Memorial Sloan Kettering Cancer Center: P Scardino*, P Fearn*,
V Reuter*, J Eastham*, M Kattan* and H Lilja*.
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